English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background Data on the impact of empiric febrile neutropenia (FN) guidelines on resistant bacteria in pediatric oncology patients are limited. We implemented a risk-stratified guideline for empiric FN antibiotics, limiting vancomycin use to high-risk patients for 48 hours if cultures were negative. Our aim was to assess the impact of this intervention on rates of vancomycin-resistant Enterococcus (VRE) and vancomycin use. Methods We conducted a retrospective, quasi-experimental study of oncology patients ≤ 18 years with FN admitted from 2010 to 2014. Microbiologic data and inpatient antibiotic use were obtained by chart review. Risk strata incorporated diagnosis, chemotherapy phase, Down syndrome, septic shock, and typhlitis. The primary outcome was VRE incidence; all VRE isolates were included but active surveillance was only performed in intensive care units (ICUs) in both periods. We compared VRE incidence and antibiotic days of therapy (DOT) before and after the intervention using interrupted time-series analysis with segmented Poisson regression with auto-correlation. Results We identified 183 patients with 765 admissions and 382 FN episodes pre-intervention, and 185 patients with 830 admissions and 385 FN episodes post-intervention. The proportion of high-risk patients was 51% pre vs. 45% post (P = 0.06). Median length of stay for FN admissions was 7 days (IQR: 4–22) preintervention and 5 days (IQR: 3–15) postintervention (P ≤ 0.01). Median duration of empiric vancomycin decreased from 5 days (IQR: 3–9) pre- to 3 days (IQR: 3–4) postintervention (P ≤ 0.01). Empiric vancomycin DOT/1,000 FN days decreased from 287 preintervention to 199 postintervention (P ≤ 0.01). Incidence of VRE/1,000 patient-days decreased significantly from 1.71 preintervention to 0.45 postintervention (IRR=0.26, 95% CI 0.09–0.80; P = 0.02). The proportion of VRE isolates representing colonization did not differ significantly pre- and postintervention (50% vs. 67%). Conclusion Implementation of an FN guideline limiting vancomycin exposure was associated with decreased incidence of VRE among pediatric oncology patients. Antimicrobial stewardship interventions are feasible in immunocompromised patients and can impact antibiotic resistance. Disclosures All authors: No reported disclosures.

280. The Impact of a Revised Neutropenic Fever Guideline on Vancomycin-Resistant Enterococcus Rates in Pediatric Oncology Patients